TY - JOUR
T1 - Challenges and opportunities in research funding for neurovascular diseases from a clinical researcher's perspective
AU - Ospel, Johanna Maria
AU - McDonough, Rosalie
AU - Ganesh, Aravind
AU - Sehgal, Arshia
AU - Kappelhof, Manon
AU - Kashani, Nima
AU - Klijn, Karin
AU - Hill, Michael
AU - Saver, Jeffrey
AU - Goyal, Mayank
N1 - Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Xxxxxxx.Michael Hill: Grants to the University of Calgary from Boehringer-Ingelheim for the TEMPO-2 trial, grants to the University of Calgary from Biogen Inc., grants to the University of Calgary from CIHR and NoNO Inc. for the ESCAPE-NA1 trial, Grants to the University of Calgary from Alberta Innovates to the University of Calgary for QuICR Alberta Stroke Programd and the ESCAPE-NA1 trial, US Patients 62/086,077 and 10,916,346 licensed to Circle NVI, DSMC Chari for the RACECAT, Oncovir Hiltonel, DUMAS, ARTESIA and BRAIN-AF trials, president of the Canadian Neurological Sciences Federation, board member of the Canadian Stroke Consortium, board member, founder and part ownership Circle NVI. Mayank Goyal: Unrestricted grants to the University of Calgary from Medtronic, grants to the University of Calgary from Cerenovus, NoNO Inc., royalties from GE Healthcare and Microvention, consulting fees from Medtronic, Stryker, Microvention, Mentice, Philips, stock options from Circle NVI. Jeffrey Saver: Stock options from Rapid Medical. Aravind Ganesh: grants to the University of Calgary from CIHR, Canadian Cardiovascular Society, Alberta Innovates, Campus Alberta Neuroscience, Sunnybrook Research Institute INOVAIT Program, consulting fees from MD Analytics, MyMedicalPanel, Figrue 1, CTC Communications Group, Atheneum, DeepBench, Research on Mind, Creative Research Designs, honoraria for lectures, Alexion, travel support from American Academy of Neurology, Association of Indian Neurologists in America, American Heart Association, University of Calgary, US patent 17/317,771 filed, editorial board member Neurology:Clinical Practice, Neurology, Stroke, stock options from SnapDX, Advanced Health Analytics (AHA Health Ltd.), TheRounds.com. Karin Klijn: grants from the Dutch HeartFoundation (grant 2012T077); The Netherlands Organization for Health Research and Development, ZonMw (grant 015008048); support of the Netherlands Cardiovascular Research Initiative, which is supported by the Dutch Heart Foundation, CVON2015–01: CONTRAST, and the support of the Brain Foundation Netherlands (HA2015·01·06). The remaining authors have nothing to disclose. Publisher Copyright: © The Author(s) 2022.
PY - 2022
Y1 - 2022
N2 - Background & Purpose: Neurovascular research is underfunded, imposing substantial challenges on clinical researchers in the field of neurovascular diseases. We explored what physicians perceive to be the greatest challenges with regard to neurovascular research funding, and how they think the funding crisis in neurovascular research could be overcome. Methods: We performed an international, multi-disciplinary survey among physicians involved in the medical care of patients with neurovascular diseases. After providing their demographic data, physicians were asked closed-ended questions on their personal opinion regarding challenges in neurovascular research funding, and how these challenges could be overcome. Physicians also described in their own words what they perceived to be the biggest challenges in obtaining funding. Data were analyzed using descriptive statistics and response clustering. Results: Of 233 participating physicians (70.4% male,82.8% senior staff) from 48 countries, 217(97.4%) perceived the discrepancy between required and available funding to be a problem;172(73.8%) considered it a major problem. High competitiveness (61/118 available free text responses[51.7%]), time-consuming application processes (28/118[23.7%]) and administrative requirements (25/118[21.1%]) were identified as key obstacles. Traditional big funding agencies were perceived to be most capable of closing the neurovascular research funding gap, followed by specialty-specific organizations and industry, while philanthropy and crowdfunding were perceived to be less important. Conclusion: The gap between required and available funding was perceived to be a major problem in neurovascular research, with high competitiveness, time-consuming funding processes and excessive administrative requirements being the key obstacles to obtaining funding. Traditional funding agencies were perceived to be most capable of closing this funding gap.
AB - Background & Purpose: Neurovascular research is underfunded, imposing substantial challenges on clinical researchers in the field of neurovascular diseases. We explored what physicians perceive to be the greatest challenges with regard to neurovascular research funding, and how they think the funding crisis in neurovascular research could be overcome. Methods: We performed an international, multi-disciplinary survey among physicians involved in the medical care of patients with neurovascular diseases. After providing their demographic data, physicians were asked closed-ended questions on their personal opinion regarding challenges in neurovascular research funding, and how these challenges could be overcome. Physicians also described in their own words what they perceived to be the biggest challenges in obtaining funding. Data were analyzed using descriptive statistics and response clustering. Results: Of 233 participating physicians (70.4% male,82.8% senior staff) from 48 countries, 217(97.4%) perceived the discrepancy between required and available funding to be a problem;172(73.8%) considered it a major problem. High competitiveness (61/118 available free text responses[51.7%]), time-consuming application processes (28/118[23.7%]) and administrative requirements (25/118[21.1%]) were identified as key obstacles. Traditional big funding agencies were perceived to be most capable of closing the neurovascular research funding gap, followed by specialty-specific organizations and industry, while philanthropy and crowdfunding were perceived to be less important. Conclusion: The gap between required and available funding was perceived to be a major problem in neurovascular research, with high competitiveness, time-consuming funding processes and excessive administrative requirements being the key obstacles to obtaining funding. Traditional funding agencies were perceived to be most capable of closing this funding gap.
KW - Neurovascular research
KW - clinician-scientist
KW - research funding
UR - http://www.scopus.com/inward/record.url?scp=85125757116&partnerID=8YFLogxK
U2 - https://doi.org/10.1177/15910199221084801
DO - https://doi.org/10.1177/15910199221084801
M3 - Article
C2 - 35238671
SN - 1591-0199
JO - Interventional neuroradiology
JF - Interventional neuroradiology
ER -